Pasqal stock initiated with buy rating at Roth/MKM on quantum tech

Roth/MKM initiated Pasqal SAS (PSQL) at Buy with a $20 price target, implying roughly 149% upside from the cited $8.04 share price, despite the stock falling 34% over the prior week and 19% year-to-date. The $1.71 billion quantum-computing company is pursuing a Nasdaq listing through its combination with Bleichroeder Acquisition Corp. II, which is expected to provide cash for commercialization of its neutral-atom systems. The bullish thesis centers on expanding demand for quantum and hybrid AI-quantum computing, global deployments, sovereign support from France, and partnerships including Credit Agricole CIB for capital-markets use cases targeted for production by 2028.

Analysis

The actionable issue is not the stated target price but financing quality. For a pre-revenue quantum company entering public markets through a SPAC, the relevant valuation hinges on pro forma trust cash after redemptions, PIPE terms, sponsor promote dilution, warrant overhang, and the runway to the first independently disclosed recurring revenue—not technology claims or partnership announcements. Until the definitive merger filings establish these variables, a $20 target is not a usable valuation anchor; the low float and retail ownership typical of de-SPACs can create sharp upside squeezes but also sustained post-lockup pressure.

Neutral-atom computing may ultimately offer a differentiated scaling path, but commercial adoption remains bottlenecked by error correction, uptime, integration costs, and customers' willingness to pay before quantum advantage is demonstrated. The cited financial-services production timetable implies that material revenue validation is likely years away, while cash burn and engineering hiring are immediate. This favors better-capitalized ecosystem beneficiaries—HPE through HPC/AI integration and potentially NDAQ only through modest listing-related fees—rather than treating either as a meaningful read-through trade.

Over the next days, any analyst-driven rebound is likely technical rather than fundamental. The 1-3 month catalyst path is merger-document disclosure and redemption outcomes; over 6-18 months, the key risk is multiple compression if the company cannot convert pilots into contracted backlog and quantify gross-margin trajectory. A credible falsifier of the cautious stance would be fully funded 24+ month liquidity, limited dilution, and customer contracts with disclosed minimum commitments rather than nonbinding collaborations.

Key Decisions for Investors

• No directional PSQL position before the merger proxy/S-4 and final closing documents disclose pro forma cash, redemptions, PIPE price, sponsor promote, warrant treatment, and lockup expiration. Treat an initial rally without those disclosures as a liquidity event, not confirmation of fundamental value.
• Set a post-listing alert: consider a tactical short only after lockup and warrant registration dates are known, if enterprise value remains above comparable quantum peers despite less than 12 months of disclosed cash runway or no contracted revenue backlog. Cover on evidence of funded runway exceeding 24 months or a material customer prepayment.
• For liquid exposure to the AI/HPC buildout, prefer a 6-12 month long HPE only if enterprise AI/HPC orders and margin guidance improve; Pasqal personnel ties alone do not alter HPE earnings. Invalidate if HPE infrastructure revenue guidance deteriorates or AI order conversion fails to lift backlog.
• Do not use NDAQ as a proxy for this transaction: incremental listing economics are immaterial to its earnings base. Monitor only for broader IPO/de-SPAC issuance acceleration, which would be the mechanism capable of affecting NDAQ valuation.